tiprankstipranks
Gossamer Bio announces TORREY study meets primary endpoint
The Fly

Gossamer Bio announces TORREY study meets primary endpoint

Gossamer Bio announced topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension, or PAH. Seralutinib is a tyrosine kinase inhibitor targeting PDGFRa/ss, CSF1R, and c-KIT, specifically designed to be delivered via dry powder inhaler for the treatment of pulmonary hypertension. The Phase 2 TORREY study enrolled 86 patients with WHO Functional Class, or FC, II or III PAH, with 42 randomized to the placebo arm and 44 randomized to the seralutinib arm. The primary endpoint of the study was change from baseline to Week 24 in pulmonary vascular resistance, or PVR. The secondary endpoint was change in six-minute walk distance, or 6MWD, from baseline to Week 24. Patients remained on their background PAH therapies during the study. At baseline, 57% of patients were on background triple therapy, consisting of three classes of vasodilator treatments. The mean baseline PVR and 6MWD of randomized patients were ~669 dynes*s/cm5 and ~408 meters, respectively. The treatment and placebo arms were generally well balanced, except for baseline WHO Functional Class: 20 FC II and 22 FC III patients were randomized to the placebo arm, while 30 FC II and 14 FC III patients were randomized to the seralutinib arm.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on GOSS:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles